Inventor
Nikolaos PAPAIOANNOU
Inventor
US
Overview
Patents· 10 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
C07DHeterocyclic compounds33%
A61KPreparations for medical, dental or toiletry purposes17%
C07CAcyclic or carbocyclic compounds10%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium7%
PatentTitleYear
12,441,724Inhibitors of plasma kallikrein and uses thereof202512,221,441Plasma kallikrein inhibitors and uses thereof202512,202,836Bicyclic-fused heteroaryl or aryl compounds202512,065,448Heteroaryl plasma kallikrein inhibitors202411,905,285Inhibitors of plasma kallikrein and uses thereof202411,787,796Plasma Kallikrein inhibitors and uses thereof202311,702,424Bicyclic-fused heteroaryl or aryl compounds202311,603,349Anti-fibrotic compounds202311,370,803Heteroaryl plasma kallikrein inhibitors202211,352,356Inhibitors of plasma kallikrein and uses thereof2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2025Patents assigned to TAKEDA PHARMACEUTICALS CO (7)· patent assignee history
2022–2025Based in US· patent location history
2023–2025Patents assigned to PFIZER (2)· patent assignee history
2023Patents assigned to CERTA THERAPEUTICS PTY LTD (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| TAKEDA PHARMACEUTICALS CO | 7 | 2022–2025 |
| PFIZER | 2 | 2023–2025 |
| CERTA THERAPEUTICS PTY LTD | 1 | 2023 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 10 | 2022–2025 |